CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...
This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.
Investor's Business Daily on MSN
CRISPR Therapeutics shows rising price performance with jump to 82 RS rating
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 71 to 82.
Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...
Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...
To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...
It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction.
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback